Improving FCR immunochemotherapy in CLL

Blood

Volumn 115, Issue 3, 2010, Pages 437-438

  Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; LUMILIXIMAB; MITOXANTRONE; RITUXIMAB;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG BINDING; HUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE;

EID: 77950524161     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-10-251249     Document Type: Note

References (10)

1. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4070-4078.
2. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079-4088.
3. Hallek M, Fingerle-Rowson G, Fink AM, et al. Immunochemotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival (PFS) of previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL) [abstract]. Blood. 2008;112(11):125. Abstract 325.
4. Robak T, Moiseev S, Dmoszynska A, et al. Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone: final results from the international randomized phase III REACH trial [abstract]. Blood. 2008;112(11):LBA-1. Abstract 157420.
5. Pathan NI, Chu P, Hariharan K, et al. Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. Blood. 2008;111(3):1594-1602.
6. Byrd JC, O'Brien SO, Flinn IW, et al. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmaco-dynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007; 13(15 Pt 1):4448-4455.
7. Byrd JC, Kipps TJ, Flinn IW, et al. Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. Blood. 2010;115(3):489-495.
8. Lumiliximab with fludarabine, cyclophosphamide, and rituximab (FCR) versus FCR alone in subjects with relapsed chronic lymphocytic leukemia (CLL) (LUCID. http://clinicaltrials.gov. Verified by Biogen Idec, September 2009. Updated September 25, 2009. Accessed November 19, 2009.
9. Wierda WG, O'Brien SM, MD, Faderl SH, et al. Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR), an active regimen for heavily treated patients with CLL [abstract]. Blood. 2006;108:14a. Abstract 31.
10. Hillmen P, Pcock C, Cohen D, et al. NCRI CLL201 Trial: A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated CLL [abstract]. Blood. 2007;110:231a. Abstract 752.